Ribobay Pharma
Nanjing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing novel small molecule drugs for cancer and infectious diseases.
OncologyInfectious Disease
Technology Platform
Utilizes structure-based drug design and computational chemistry to develop novel, optimized small molecule therapeutics.
Opportunities
Potential to address significant unmet needs with novel mechanisms, particularly in antimicrobial resistance and niche oncology targets.
Risk Factors
High clinical attrition risk inherent in small molecule drug development, especially in crowded therapeutic areas like oncology.
Competitive Landscape
Operates in the highly competitive fields of oncology and anti-infectives, where it must compete on target novelty and clinical data against both large pharma and other biotechs.